Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative diseases that occur either in relatively rare, familial forms or in common, sporadic forms. The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear. To gain insights into the pathogenic mechanisms involved in AD and PD, we used a proteomic approach to identify proteins with altered expression levels and/or oxidative modifications in idiopathic AD and PD brains. Here, we report that the protein level of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), a neuronal de-ubiquitinating enzyme whose mutation has been linked to an early-onset familial PD, is down-regulated in idiopathic PD as well as AD brains. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified three human brain UCH-L1 isoforms, a full-length form and two amino-terminally truncated forms. Our proteomic analyses reveal that the full-length UCH-L1 is a major target of oxidative damage in AD and PD brains, which is extensively modified by carbonyl formation, methionine oxidation, and cysteine oxidation. Furthermore, immunohistochemical studies show that prominent UCH-L1 immunostaining is associated with neurofibrillary tangles and that the level of soluble UCH-L1 protein is inversely proportional to the number of tangles in AD brains. Together, these results provide evidence supporting a direct link between oxidative damage to the neuronal ubiquitination/de-ubiquitination machinery and the pathogenesis of sporadic AD and PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dysfunction contributes to neuronal damage and death by several mechanisms, including ER stress and the accumulation of oxidatively damaged proteins, which in the normal brain are usually degraded by the UPS and autophagy to keep their levels low8,50,53,55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“a crucial part of the UPS is oxidatively damaged and dysfunctional in both aMCI and AD brain, namely, ubiquitin carboxyl-terminal hydrolase L-1 (UCH L1)34,55–57.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
In the citing paper
“the failure of oxidatively damaged UCH L1 to perform its function in aMCI and AD brains leads to accumulation of ubiquitinylated proteins, decreased proteasome function, and subsequent accumulation of damaged, aggregated proteins55.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [55]
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Roepstorff, P., & Fohlman, J. (1984) · Biological Mass Spectrometry · doi:10.1002/bms.1200111109 · Cited by 2,633
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Oxidant signals and oxidative stress
Finkel, T. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00002-4 · Cited by 1,393
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Methionine residues as endogenous antioxidants in proteins
Levine, R. L., Mosoni, L., Berlett, B. S., & Stadtman, E. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15036 · Cited by 1,041
The Neuron-Specific Protein PGP 9.5 Is a Ubiquitin Carboxyl-Terminal Hydrolase
Wilkinson, K. D., Lee, K., Deshpande, S., Duerksen-Hughes, P., Boss, J. M., & Pohl, J. (1989) · Science · doi:10.1126/science.2530630 · Cited by 871
Research works printed but not linked: 2
- Ischiropoulos, 2003, J. Clin. Invest., 111, 163, 10.1172/jci200317638 · DOI · Paper page
- Wu, 1996, Alzheimer's Res., 2, 163
Cited by
Items 401–500 of 571
Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 17
Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1
Shimshek, D. R., Schweizer, T., Schmid, P., & van der Putten, P. H. (2012) · Scientific Reports · doi:10.1038/srep00262 · Cited by 17
“; (ii) UCH-L1 levels are reduced and activity is down by 40-80% because of oxidative damage in idiopathic PD, DLB and AD brain”
BackgroundMartinez, A., Ramírez, J., Osinalde, N., Arizmendi, J. M., & Mayor, U. (2018) · BioMed Research International · doi:10.1155/2018/3180413 · Cited by 16
“Similarly, downregulation of the DUB enzyme UCHL1 has also been linked with Parkinson’s and Alzheimer’s disease [31, 32].”
BackgroundHewitt, C. S., Krabill, A. D., Das, C., & Flaherty, D. P. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b01076 · Cited by 18
Pathology of Neurodegenerative Diseases
Kim, Y. S., Kim, Y.-K., Hwang, O., & Dong, J. (2012) · InTech eBooks · doi:10.5772/38028 · Cited by 20
Liu, J., Jiang, Y., Huang, C.-Y., Fang, H., Fang, H., & Pang, W. (2008) · Nutritional Neuroscience · doi:10.1179/147683013x13789826942468 · Cited by 17
Proteasome inhibition: An early or late event in nitric oxide-induced neuronal death?
Peng, Z. F., Chen, M. J., Yap, Y. W., Manikandan, J., Melendez, A. J., Choy, M. S., Moore, P. K., & Cheung, N. S. (2007) · Nitric Oxide · doi:10.1016/j.niox.2007.11.002 · Cited by 17
How proteomics reveals potential biomarkers in brain diseases
Schmidt, O., Schulenborg, T., Meyer, H. E., Marcus, K., & Hamacher, M. (2005) · Expert Review of Proteomics · doi:10.1586/14789450.2.6.901 · Cited by 19
Guglielmotto, M., Repetto, I. E., Monteleone, D., Vasciaveo, V., Franchino, C., Rinaldi, S., Tabaton, M., & Tamagno, E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190494 · Cited by 15
“Indeed, Uch-L1, the limiting step of proteasomal degradation, is decreased in AD brains [12], and its level is inversely proportional to the amount of tau pathology [13].”
Rong, C., Zhou, R., Wan, S., Su, D., Wang, S., & Heß, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592501 · Cited by 15
“For instance, the specific distribution and activity of UCHL1 in human tissues has the potential clinical significance for Parkinson’s disease (PD) and Alzheimer’s disease (AD), might be a major target of reactive oxygen species (ROS) damage (40).”
BackgroundUCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?
Cui, J., & Xie, X. (2017) · Inflammation · doi:10.1007/s10753-017-0512-x · Cited by 15
Liu, Q.-X., Zhang, W., Wang, J., Hou, W., & Wang, Y. (2017) · Journal of Ginseng Research · doi:10.1016/j.jgr.2017.04.006 · Cited by 15
“However, UCHL1 overexpression has been shown to delay AD progression in vivo [19], and low levels have also been reported in postmortem brain tissue from AD patients [20].”
BackgroundWeber, B., Schaper, C., Wang, Y., Scholz, J., & Bein, B. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.05.011 · Cited by 15
Smith, R. W. P., Cash, P., Hogg, D. W., & Buck, L. T. (2015) · PROTEOMICS · doi:10.1002/pmic.201300229 · Cited by 14
Fu, Y., Zhao, D., Pan, B., Wang, J., Cui, Y., Shi, F., Wang, C., Yin, X., Zhou, X., & Yang, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150312 · Cited by 18
Puri, S., & Hsu, S. D. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.02.029 · Cited by 14
UCH-L1 in Alzheimer’s Disease: A Crucial Player in Dementia-Associated Mechanisms
Porchietto, E., Morello, G., Cicilese, G., Rainero, I., Rubino, E., Tamagno, E., Boschi, S., & Guglielmotto, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189012 · Cited by 14
“The relevance of UCH-L1’s protective effects is proven by the fact that it is reduced in post-mortem brains with AD [21,41,42], even if conflictual reports have been documented [18].”
InfluentialKonya, C., Hatanaka, Y., Fujiwara, Y., Uchida, K., Nagai, Y., Wada, K., & Kabuta, T. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.012 · Cited by 13
Liu, Q. Y., Sooknanan, R., Malek, L. T., Ribecco‐Lutkiewicz, M., Lei, J. X., Shen, H., Lach, B., Walker, P. R., Martin, J., & Sikorska, M. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-286 · Cited by 13
Zhu, L., Zhao, D., & Yang, L. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt020 · Cited by 14
Matsuura, K., Otani, M., Takano, M., Kadoyama, K., & Matsuyama, S. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.025 · Cited by 13
The interactome of 2-Cys peroxiredoxins in Plasmodium falciparum
Brandstädter, C., Delahunty, C. M., Schipper, S., Rahlfs, S., Yates, J. R., & Becker, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-49841-3 · Cited by 13
Yi, D., & Perkins, P. D. (2005) · PubMed · Cited by 13
Moyano, P. M., Solà, E., Naval, M. V., Guerra-Menéndez, L., Fernández, M. D. L. C., & del Pino, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082048 · Cited by 12
Proteomics and lipidomics in the human brain
Ferrer, I. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63639-3.00020-7 · Cited by 13
Ubiquitin C-terminal Hydrolase L1 Regulates Lipid Raft-dependent Endocytosis
Kang, S., Kim, J. S., & Park, S. M. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.5.377 · Cited by 13
Pedrero-Prieto, C. M., Frontiñán-Rubio, J., Alcain, F. J., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11091655 · Cited by 14
Genetic Predisposition to Parkinson’s Disease and Cancer
Li, Z., Lin, Q., Ma, Q., Lu, C., & Tzeng, C. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140312145936 · Cited by 11
Long, L., Wu, P., Guan, X., Zhang, J.-Q., Jin, Y., Zhang, Z., Wang, Y., Li, Y.-Y., Chen, J., & Wang, F. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4604-9 · Cited by 11
Li, N., Hu, P., Xu, T., Chen, H., Chen, X., Hu, J., Yang, X., Shi, L., Luo, J., & Xu, J. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170719165745 · Cited by 11
Aberrant energy metabolism and redox balance in seizure onset zones of epileptic patients
Grove, R. A., Madhavan, D., Boone, C. H. T., Braga, C. P., Papáčková, Z., Kyllo, H. M., Samson, K. K., Simeone, K. A., Simeone, T. A., Helikar, T., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103812 · Cited by 11
Kim, H., Lee, J.-Y., Park, S.-J., Kwag, E., Kim, J., & Shin, J. (2022) · Cells · doi:10.3390/cells11223682 · Cited by 12
Zhao, X. S., Li, Q., Zhao, L., & Pu, X. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700077 · Cited by 12
Ubiquitin C-terminal hydrolase L1 interacts with choline transporter in cholinergic cells
Hartnett, S., Zhang, F., Abitz, A., & Li, Y. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.02.007 · Cited by 11
McLeod, V. M., Chiam, M. D. F., Perera, N. D., Lau, C. L., Boon, W. C., & Turner, B. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.808479 · Cited by 10
“Additionally, the UCHL1 gene is known to be downregulated in sporadic ALS motor cortex (41), hence, it may be lost in a disease-progressive manner, as is the case in several other neurodegenerative disorders (42, 43).”
ResultMatsuura, K., Otani, M., Takano, M., Kadoyama, K., & Matsuyama, S. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8953015 · Cited by 11
“UCH-L1 is downregulated in the brain of patients with Parkinson’s disease and AD [39].”
BackgroundEvaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy
Yasak, İ. H., Yılmaz, M., Gönen, M., ATESCELIK, M., Gürger, M., İlhan, N., & Göktekin, M. Ç. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20200040 · Cited by 10
Zhang, Y., Huang, X., Zhao, X., Hu, Y., Sun, H., & Kong, W. (2017) · ORL · doi:10.1159/000468944 · Cited by 10
Liu, J., Jiang, Y., Huang, C., Fang, H., Fang, H., & Pang, W. (2010) · Electrophoresis · doi:10.1002/elps.200900733 · Cited by 10
Recent updates on drug abuse analyzed by neuroproteomics studies: Cocaine, Methamphetamine and MDMA
Kobeissy, F. H., Mouhieddine, T. H., Nokkari, A., Itani, M. M., Mouhieddine, M., Zhang, Z., Zhu, R., Gold, M. S., Wang, K., & Mechref, Y. S. (2014) · Translational Proteomics · doi:10.1016/j.trprot.2014.04.001 · Cited by 11
“UCH-L1 was found to be involved in germ cell and neuronal apoptosis [ 104 ] and in the degenerative process of Alzheimer ’ s and Parkinson ’ s diseases [ 105 , 106 ].”
BackgroundGraham, S. H. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.184482 · Cited by 9
“Oxidative modification and down-regulation of UCHL1 has been detected in idiopathic PD and AD brains (Choi et al., 2004).”
Isopeptidases in anticancer therapy: looking for inhibitors.
Sgorbissa, A., Potu, H., & Brancolini, C. (2010) · PubMed · Cited by 9
Genetics of Parkinson's Disease
Huang, Y. M., Chan, P., & Halliday, G. M. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50169-1 · Cited by 12
Ávila, D. S., Puntel, R. L., Folmer, V., da Rocha, J. B. T., dos Santos, A. P. M., & Aschner, M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_3 · Cited by 12
Functional dynamics of human ubiquitin C-terminal hydrolases
Puri, S., & Hsu, S. D. (2024) · Frontiers in Biophysics · doi:10.3389/frbis.2024.1479898 · Cited by 8
Magini, A., Urbanelli, L., Ciccarone, V. A., Tancini, B., Polidoro, M., Timperio, A. M., Zolla, L., Tedde, A., Sorbi, S., & Emiliani, C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091522 · Cited by 9
“Downregulation and extensive oxidative modification of UCH-L1 have been observed in the brain of AD as well as Parkinson’s disease patients: the observation of decreased level of this protein at peripheral level could represent a diminished defensive response to amyloid fibrils formation [76–78].”
pink1, atp13a2 and uchl1 expressions are affected by inflammation in the brain
Moriya, S., Tan, V. P. Y., Yee, A. K., & Parhar, I. S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134330 · Cited by 10
Çetin, İ., Tezdig, I., Tarakçıoğlu, M. C., Kadak, M. T., Demirel, Ö. F., Özer, Ö. F., Erdoğan, F., & Doğangün, B. (2017) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2017.14873 · Cited by 8
Backbone assignments of the 26 kDa neuron-specific ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1)
Andersson, F. I., Jackson, S., & Hsu, S. D. (2009) · Biomolecular NMR Assignments · doi:10.1007/s12104-009-9203-3 · Cited by 8
“In addition, there is significant evidence of oxidative/carbonyl stress damage to UCH-L1 in the brains of patients with sporadic PD (Choi et al. 2004).”
BackgroundWang, S., Dong, K., Zhang, J., Chen, C., Shuai, H., & Yu, X. (2023) · Nutrition Research and Practice · doi:10.4162/nrp.2023.17.6.1128 · Cited by 7
“The down regulation of both UCHL1 mRNA and UCHL1 protein has been detected in AD [26].”
BackgroundDellar, E. R., Vendrell, I., Amein, B., Lester, D., Edmond, E., Yoganathan, K. T., Dharmadasa, T., Sogorb‐Esteve, A., Fischer, R., Talbot, K., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27133 · Cited by 7
Long Non-coding RNAs Associated with Brain Disorders: A Literature Review
Abdolmaleki, A., Ferdowsi, S., Asadi, A., & Panahi, Y. (2021) · Gene Cell and Tissue · doi:10.5812/gct.111802 · Cited by 7
Kinumi, T., Osaka, I., Hayashi, A., KAWAI, T., Matsumoto, H., & Tsujimoto, K. (2009) · Journal of the Mass Spectrometry Society of Japan · doi:10.5702/massspec.57.371 · Cited by 7
UCH-L1 Inhibition Involved in CREB Dephosphorylation in Hippocampal Slices
Xie, M., Wang, S., Lu, Z., Pan, Y., Chen, Q.-C., & Liao, X. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0197-z · Cited by 7
“2005) which prominent associated with UCH-L1 in AD brains (Choi et al. 2004).”
BackgroundInfluentialChlorogenic acid modulates the ubiquitin–proteasome system in stroke animal model
Shah, M.-A., Kang, J.-B., & Koh, P. (2022) · Laboratory Animal Research · doi:10.1186/s42826-022-00151-2 · Cited by 7
Use of a phosphosensor dye in proteomic analysis of human mutant tau transgenic mice
Takano, M., Otani, M., Sakai, A., Kadoyama, K., Matsuyama, S., Matsumoto, A., Takenokuchi, M., Sumida, M., & Taniguchi, T. (2009) · Neuroreport · doi:10.1097/wnr.0b013e328333b0e0 · Cited by 7
Conti, A., & Alessio, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.004 · Cited by 9
Joseph, S. J., Robbins, K. R., Zhang, W., & Rekaya, R. (2008) · In Silico Biology · doi:10.3233/isb-00377 · Cited by 8
Hellström, S., Sajanti, A., Jhaveri, A., Srinath, A., Bennett, C., Cao, Y. J., Koskimäki, F., Falter, J., Frantzén, J., Lyne, S. B., et al. (2024) · Brain and Spine · doi:10.1016/j.bas.2024.104173 · Cited by 6
“Reduced UCH-L1 activity has been linked to neurodegenerative diseases such as Alz-heimer ’ s and Parkinson ’ s disease (Choi et al., 2004).”
Post-translational Modifications in Parkinson’s Disease
Antunes, A. S. L. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-05460-0_6 · Cited by 6
Ferreira, M., Martins, T. S., Alves, S. R., Rosa, I. M., Vogelgsang, J. S., Hansen, N., Wiltfang, J., Silva, O. A. B. D. C. E., Vitorino, R. M. P., & Henriques, A. G. (2023) · PROTEOMICS · doi:10.1002/pmic.202200515 · Cited by 6
Kandpal, M., Varshney, N., Rawal, K. S., & Jha, H. C. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.02.001 · Cited by 7
How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection
Tóth, M. E., Sántha, M., Penke, B., & Vígh, L. (2015) · Heat shock proteins · doi:10.1007/978-3-319-16077-1_23 · Cited by 6
The ubiquitin-proteasome system in normal hearing and deafness
Pouyo, R., Chung, K., Delacroix, L., & Malgrange, B. (2021) · Hearing Research · doi:10.1016/j.heares.2021.108366 · Cited by 7
UV induced changes in proteome of rats plasma are reversed by dermally applied cannabidiol
Gęgotek, A., Atalay, S., & Skrzydlewska, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-00134-8 · Cited by 6
Yu, X., Ponce, R. A., & Faustman, E. M. (2011) · Springer eBooks · doi:10.1007/978-94-007-0428-2_14 · Cited by 6
Oroján, I., Bakota, L., & Gulya, K. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.015 · Cited by 5
Suk, K. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.3.237 · Cited by 6
“In the study that utilised frontal cortex tissues of PD patients rather than substantia nigra, oxidative modification of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) was the major finding of proteomic analysis [37].”
BackgroundInflammation as a Mediator of Oxidative Stress and UPS Dysfunction
Schmidt‐Glenewinkel, T., & Figueiredo‐Pereira, M. E. (2007) · Springer eBooks · doi:10.1007/0-387-28500-8_7 · Cited by 6
Nakamura, T., Sharma, A., & Lipton, S. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00708 · Cited by 7
Pivotal Role of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) in Uterine Leiomyoma
Suzuki, T., Dai, Y., Ono, M., Kojima, J., Sasaki, T., Fujiwara, H., Kuji, N., & Nishi, H. (2023) · Biomolecules · doi:10.3390/biom13020193 · Cited by 5
“According to some previous studies, UCHL1 expression significantly increases in some cancer cells [26,27] and decreases in the brains of Parkinson’s and Alzheimer’s disease patients [28].”
ResultMi, Z., Povysheva, N. V., Rose, M. E., Ma, J., Zeh, D. J., Harikumar, N., Bhuiyan, M. I. H., & Graham, S. H. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241258809 · Cited by 5
Joseph, S. J., Robbins, K. R., & Rekaya, R. (2006) · Conference proceedings · doi:10.1109/iembs.2006.259371 · Cited by 5
“... a role in cellular differentiation and proliferation [12], Alpha Synuclein (ASN) which is a heatstable protein present more abundantly in telencephalon [13] and was recently considered as a major factor in the pathogenesis of AD [14], a mutant of the ubiquitin gene (UCH-L1) which might lead to dysfunction of the n…”
BackgroundInteraction Between α-Synuclein and DJ-1 in Parkinson’s Disease
Sobhifar, P., & Brown, D. R. (2025) · Brain Sciences · doi:10.3390/brainsci15090899 · Cited by 5
“The inactive sulfonic form of DJ-1 was detected in patients with sporadic PD [83].”
UCHL1-Mediated Spastin Degradation Regulates Microtubule Severing and Hippocampal Neurite Outgrowth
Ma, A., Liang, Z., Zhang, H., Meng, Z., Zhu, J., Chen, S. G., Lin, Q., Jiang, T., & Tan, M. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02348-1 · Cited by 4
“For example, UCHL1 downregulation can be found in Parkinson’s disease and Alzheimer’s disease (Choi et al. 2004).”
Heparanase Modulation of Early Growth Response Gene Expression
Xia, Y., Jin, S., Li, S.-B., Gong, F., Zhang, D., Zhang, X., & Li, J. (2011) · ZOOLOGICAL SCIENCE · doi:10.2108/zsj.28.189 · Cited by 4
“, Uchl1 (ubiquitin carboxyl-terminal hydrolase isozyme L1), which encodes an enzyme almost exclusively expressed in neurons and associated with Parkinson’s disease (Choi et al., 2004); and Gabra6 (gamma-aminobutyric acid (GABA) A receptor 6), which encodes a receptor for the chief inhibitory neurotransmitter in the ce…”
BackgroundMudawal, A., Srivastava, A., Singh, A., Shankar, J., Yadav, S., Mishra, M., Singh, P. K., Khanna, V. K., & Parmar, D. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.03.049 · Cited by 4
Dithranol abolishes UCH-L1 immunoreactivity in the nerve fibers of the rat orofacial skin
Orojan, I., Szigeti, C., Várszegi, S., Dobó, E., & Gulya, K. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.088 · Cited by 4
Contribution of Disturbed Iron Metabolism to the Pathogenesis of Parkinson‘s Disease
Berg, D., Riederer, P. F., & Gerlach, M. (2008) · Future Neurology · doi:10.2217/14796708.3.4.447 · Cited by 4
Tsai, C., Pai, P., Ho, Y., Lu, J., Wang, J., Lin, W., & Her, G. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2857 · Cited by 4
Brain Protein Oxidation and Modification for Good or for Bad in Alzheimer’s Disease
Sultana, R., & Butterfield, D. A. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_17 · Cited by 5
Berg, D. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50148-4 · Cited by 4
Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries
Sivandzade, F., Alqahtani, F., Dhaibar, H. A., Cruz‐Topete, D., & Cucullo, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076219 · Cited by 3
“UCH-L1 is a biomarker of TBI severity [93]; it is highly expressed in neurons and is a major target of OS where increased ROS induces oxidative modification of UCH-L1, leading to pathological alteration of their cellular function [94,95].”
BackgroundStimulation of Tau Degradation
Quintanilla, R. A., Cabezas-Opazo, F., Pallo, S. P., Chesser, A. S., & Johnson, G. V. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00013-7 · Cited by 3
Anamorsin attenuates cupric chloride-induced dopaminergic neuronal cell death
Park, K.-A., Yun, N., & Oh, Y. J. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.089 · Cited by 3
Folk, D. S., Kielar, F., & Franz, K. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-08-097774-4.00315-6 · Cited by 3
Proteome profile changes in SH-SY5y neuronal cells after treatment with neurotrophic factors
Park, S., & Lee, J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23316 · Cited by 3
“…UCH-L1 isoforms, a full-length form and two amino-terminally truncated 3848 PROTEOME ANALYSIS AND CYTOSKELETAL PROTEIN CHANGES JOURNAL OF CELLULAR BIOCHEMISTRY JOURNAL OF CELLULAR BIOCHEMISTRY PROTEOME ANALYSIS AND CYTOSKELETAL PROTEIN CHANGES 3849 forms, have been reported [Choi et al., 2004].”
BackgroundKwon, J., & Wada, K. (2007) · Springer eBooks · doi:10.1007/0-387-28500-8_11 · Cited by 4
Dias, E. D. C., Vieira, A. S., WERNECK, C. C., Langone, F., Novello, J. C., & Martins‐de‐Souza, D. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0403-x · Cited by 3
“Ubiquitins, which play a pivotal role in protein degradation, synaptic function and neuronal apoptosis (Hegde and DiAntonio 2002), have been also involved in axonal loss and cell death (Mukoyama et al. 1989), schizophrenia (Martins-de-Souza et al. 2009b) and neurodegenerative disorders such as Parkinson and Alzheimer…”
BackgroundInfluentialNeurochemical Aspects of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_1 · Cited by 11
Calcagnile, M., Alifano, P., Damiano, F., Pontieri, P., & Giudice, L. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178216 · Cited by 3
“Post-mortem analyses have revealed oxidative modifications of proteins and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in the brains of both PD and AD patients [118].”
Wang, B., Li, Y., Yao, T., Shen, X., Li, H., Jiang, W., Li, X., & Zhu, Z. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00963d · Cited by 3
The Protective Effects of Ubiquitin C-Terminal Hydrolase L1 on Neurons*
Min, X. I. E., Chen, Q.-C., & Liao, X. (2010) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2010.00253 · Cited by 2
Oxidative Stress and Antioxidant Strategies in Human Diseases
Yuan, K., & Zhang, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_1 · Cited by 3
Effects of deubiquitylases on the biological behaviors of neural stem cells
Zhao, Q., Li, Y., Du, X., Chen, X., Jiao, Q., & Jiang, H. F. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22844 · Cited by 2
Proteomics Principles and Clinical Applications
Ramírez-Camacho, I., Pedraza-Vázquez, G., Rodríguez‐Hernández, K. D., Sulvarán-Guel, E., & Rivero-Segura, N. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-89601-0_6 · Cited by 2
Yubolphan, R., Joompang, A., Roytrakul, S., Boonyarat, C., Choowongkomon, K., Daduang, S., Klaynongsruang, S., & Jangpromma, N. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106354 · Cited by 2
Poto, C. D., Iadarola, P., Salvini, R., Passadore, I., Cereda, C., Ceroni, M., & Bardoni, A. (2007) · Electrophoresis · doi:10.1002/elps.200700162 · Cited by 2
In Vivo Strategies to Isolate and Characterize the Neuronal Ubiquitinated Proteome
Ramírez, J., Elu, N., Martinez, A., Lectez, B. L. P., & Mayor, U. (2017) · Neuromethods · doi:10.1007/978-1-4939-7119-0_11 · Cited by 2
Su, D., Zhang, Y., Bi, F., & Xiao, B. (2019) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2019.04.08 · Cited by 2
“[30]Choi J, Levey AI, Weintraub ST, et al.”
Background
Metadata
- Authors
- Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L.
- Affiliations
- Emory University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Li, Lian
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 13
- Pages
- 13256-13264
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2169393803
- Cited by
- 568
- References
- 38
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 20 · 2021: 36 · 2020: 16 · 2019: 16 · 2018: 22 · 2017: 28 · 2016: 24 · 2015: 26 · 2014: 34 · 2013: 29 · 2012: 30
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG010130, AG-10130, AG021489, R01AG021489)
- National Cancer Institute (P30CA054174, CA-54174)
- National Institute of Neurological Disorders and Stroke (NS-047199, R01NS047199)
- National Institute of Environmental Health Sciences (ES-12068, U54ES012068)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- UCHL1, Parkinson's disease, Alzheimer's disease, protein oxidation, carbonylation, methionine oxidation, cysteine oxidation, deubiquitination, neurofibrillary tangles, protein downregulation, brain proteome
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Brain, Chromatography, High Pressure Liquid, Coloring Agents, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Molecular Sequence Data, Mutation, Oxygen, Parkinson Disease, Mass Spectrometry, Trypsin, Immunoblotting, Electrophoresis, Gel, Two-Dimensional, Down-Regulation, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Oxidative Stress, Protein Isoforms, Proteome, Ubiquitin Thiolesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.